• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国国家卫生与临床优化研究所的政治社会学:探究英国的药品成本效益监管

The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.

作者信息

Abraham John, Balendran Gowree

机构信息

Department of Medical Education, Brighton and Sussex Universities Medical School (BSMS), Brighton, UK.

Department of Global Health and Social Medicine, King's College London, London, UK.

出版信息

Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.

DOI:10.1111/1467-9566.13878
PMID:39743684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11693927/
Abstract

The National Institute for Health and Care Excellence (NICE) was established a quarter of a century ago in 1999 to regulate the cost-effectiveness of pharmaceuticals (and other health technologies) for the NHS. Drawing on medical sociology theories of corporate bias, neoliberalism, pluralism/polycentricity and regulatory capture, the purpose of this article is to examine the applicability of those theories to NICE as a key regulatory agency in the UK health system. Based on approximately 7 years of documentary research, interviews with expert informants and observations of NICE-related meetings, this paper focuses particularly on NICE's relationship with the interests of the pharmaceutical industry compared with other stakeholder interests at the meso-organisational level. Consideration of the interaction between the UK Government and the pharmaceutical industry in relation to NICE is presented together with the analysis of revolving doors and conflicts of interest of NICE experts/advisors. The nature of policy changes over time (e.g. accelerated assessment pathways and industry fees for regulatory appraisals) and how they relate to the relevant stakeholder interests is also investigated. It is concluded that NICE is largely characterised by neoliberal corporate bias, though some elements of its organisation are also consistent with theories of capture, pluralism and polycentricity.

摘要

英国国家卫生与临床优化研究所(NICE)于25年前的1999年成立,旨在规范国民保健制度(NHS)中药物(及其他医疗技术)的成本效益。本文借鉴企业偏见、新自由主义、多元主义/多中心主义和监管俘获等医学社会学理论,旨在探讨这些理论对作为英国卫生系统关键监管机构的NICE的适用性。基于约7年的文献研究、对专家 informant 的访谈以及对与NICE相关会议的观察,本文特别关注NICE在中观组织层面与制药行业利益以及其他利益相关者利益的关系。阐述了英国政府与制药行业在NICE相关问题上的互动情况,并分析了NICE专家/顾问的旋转门现象和利益冲突。还研究了政策随时间的变化性质(如加速评估途径和监管评估的行业费用)及其与相关利益相关者利益的关系。得出的结论是,NICE在很大程度上具有新自由主义企业偏见的特征,尽管其组织的某些方面也与俘获、多元主义和多中心主义理论相符。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92f/11693927/c04401fe0e9d/SHIL-47-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92f/11693927/c04401fe0e9d/SHIL-47-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e92f/11693927/c04401fe0e9d/SHIL-47-0-g001.jpg

相似文献

1
The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.英国国家卫生与临床优化研究所的政治社会学:探究英国的药品成本效益监管
Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.
2
NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.英国国家卫生与临床优化研究所技术评估:应对多层次的不确定性和偏倚可能性
Med Health Care Philos. 2013 May;16(2):281-93. doi: 10.1007/s11019-011-9376-2.
3
Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008.部分进展:1948-2008 年监管制药行业和国民保健制度。
J Health Polit Policy Law. 2009 Dec;34(6):931-77. doi: 10.1215/03616878-2009-032.
4
Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.患者组织对英格兰国家卫生与保健优化研究所技术评估的财务利益贡献:政策回顾。
BMJ. 2019 Jan 16;364:k5300. doi: 10.1136/bmj.k5300.
5
The use of economic evaluations in NHS decision-making: a review and empirical investigation.国民健康服务体系决策中经济评估的应用:一项综述与实证研究
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175. doi: 10.3310/hta12070.
6
Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?NICE 单技术评估中的决策制定:NICE 如何纳入患者观点?
Health Expect. 2018 Feb;21(1):128-137. doi: 10.1111/hex.12594. Epub 2017 Jul 7.
7
Can the NICE "end-of-life premium" be given a coherent ethical justification?NICE“临终溢价”能否给出一个连贯的伦理辩护?
J Health Polit Policy Law. 2013 Dec;38(6):1129-48. doi: 10.1215/03616878-2373166. Epub 2013 Aug 23.
8
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysis.2000年至2020年期间英国国家卫生与临床优化研究所推荐的新药对人群健康的影响:一项回顾性分析
Lancet. 2025 Jan 4;405(10472):50-60. doi: 10.1016/S0140-6736(24)02352-3. Epub 2024 Dec 12.
10
NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.NICE 与公平?英国国家卫生与保健卓越研究所 1999-2018 年的卫生技术评估政策
Health Care Anal. 2020 Sep;28(3):193-227. doi: 10.1007/s10728-019-00381-x.

引用本文的文献

1
The NHS and the pharmaceutical industry: High risk of harmful interactions.英国国家医疗服务体系(NHS)与制药行业:存在有害相互作用的高风险。
Future Healthc J. 2025 Jun 30;12(2):100257. doi: 10.1016/j.fhj.2025.100257. eCollection 2025 Jun.
2
Editorial: Health and illness interactions.社论:健康与疾病的相互作用。
Front Sociol. 2025 Feb 11;10:1561427. doi: 10.3389/fsoc.2025.1561427. eCollection 2025.

本文引用的文献

1
Is NICE losing its standing as a trusted source of guidance?英国国家卫生与临床优化研究所(NICE)是否正在失去其作为可靠指导来源的地位?
BMJ. 2023 Nov 8;383:2571. doi: 10.1136/bmj.p2571.
2
From FDA to MHRA: are drug regulators for hire?从美国食品药品监督管理局到英国药品和保健品管理局:药品监管机构是受人雇佣的吗?
BMJ. 2022 Jun 29;377:o1538. doi: 10.1136/bmj.o1538.
3
A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding.“患者-产业复合体”?调查英国患者组织对制药公司资金的财务依赖。
Sociol Health Illn. 2022 Jan;44(1):188-210. doi: 10.1111/1467-9566.13409. Epub 2021 Dec 7.
4
Divergent spender: State-societal and meso-organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy.分散型支出者:在自由资本主义民主国家中,控制药品公共支出的国家-社会和中层组织机制。
Sociol Health Illn. 2021 Jul;43(6):1518-1539. doi: 10.1111/1467-9566.13343. Epub 2021 Jul 15.
5
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.政策影响的隐秘网络:制药业与英国各党派议会团体的互动。
PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021.
6
NICE rapid guidelines: exploring political influence on guidelines.NICE 快速指南:探讨政治对指南的影响。
BMJ Evid Based Med. 2022 Jun;27(3):137-140. doi: 10.1136/bmjebm-2020-111635. Epub 2021 Apr 13.
7
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts.在不断变化的政治背景下,对英国和美国药品安全监管的国际和时间比较分析。
Soc Sci Med. 2020 Jun;255:113005. doi: 10.1016/j.socscimed.2020.113005. Epub 2020 Apr 20.
8
Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.患者组织对英格兰国家卫生与保健优化研究所技术评估的财务利益贡献:政策回顾。
BMJ. 2019 Jan 16;364:k5300. doi: 10.1136/bmj.k5300.
9
When health technology assessment is confidential and experts have no power: the case of Hungary.当健康技术评估保密且专家没有权力时:以匈牙利为例。
Health Econ Policy Law. 2019 Apr;14(2):162-181. doi: 10.1017/S1744133118000051. Epub 2018 Mar 26.
10
A pill too hard to swallow: how the NHS is limiting access to high priced drugs.难以下咽的药丸:英国国家医疗服务体系(NHS)如何限制高价药品的获取。
BMJ. 2016 Jul 27;354:i4117. doi: 10.1136/bmj.i4117.